{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:07:02Z","timestamp":1790071622534,"version":"4.0.1"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapies targeting the epidermal growth factor receptor (EGFR) cause a spectrum of cutaneous toxicities that can compromise quality of life, treatment adherence, and cancer-treatment continuity. Persistent and phenotype-specific toxicities create a need for evidence-based adjunctive interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Our aim was to appraise product-specific clinical and mechanistic evidence for Chinese botanical drugs in EGFR-targeted therapy-associated cutaneous toxicity and to define priorities for translational development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a structured narrative search of PubMed, Web of Science Core Collection, and Scopus from inception to 7 May 2026. Evidence was classified by the highest supporting design, from controlled human studies to indirect non-EGFR or computational evidence. We appraised directness, internal validity, product characterisation, outcome measurement, precision, and reporting completeness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Discussion<\/jats:title>\n                    <jats:p>Direct human evidence for defined Chinese botanical drugs remains insufficient to establish clinical efficacy. Available studies are limited by small samples, heterogeneous products, variable background care, and incomplete reporting. EGFR-specific experimental studies provide low-certainty support for barrier injury, inflammatory amplification, and phenotype-relevant mechanisms. Evidence from non-EGFR models, isolated metabolites, and network analysis remains hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Defined Chinese botanical drugs should be evaluated only as adjuncts to standard supportive care. Progress will require standardised products, phenotype-stratified trials, prespecified patient-relevant and mechanistic outcomes, and complete reporting of safety and anticancer-treatment continuity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1931462","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:35:52Z","timestamp":1790069752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chinese botanical drugs for mitigating epidermal growth factor receptor-targeted therapy-associated cutaneous toxicity: immune mechanisms and translational pathways"],"prefix":"10.3389","volume":"17","author":[{"given":"Lu","family":"Lu","sequence":"first","affiliation":[{"name":"Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Yu","sequence":"additional","affiliation":[{"name":"Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlei","family":"Ren","sequence":"additional","affiliation":[{"name":"Qingdao Central Hospital, University of Health and Rehabilitation Sciences","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.critrevonc.2014.07.005","article-title":"Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis","volume":"93","author":"Abdel-Rahman","year":"2015","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1159\/000511869","article-title":"Prophylactic topical treatment for EGFR inhibitor-induced papulopustular rash: a randomized clinical trial","volume":"237","author":"Amitay-Laish","year":"2021","journal-title":"Dermatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2015.12.004","article-title":"Inhibition of epidermal growth factor receptor induces tumor necrosis factor-alpha via activation of peroxisome proliferator-activated receptor-gamma and nuclear factor-kappaB in sebocytes: a possible pathogenesis of papulopustular rash","volume":"82","author":"Ashida","year":"2016","journal-title":"J. Dermatological Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/exd.14728","article-title":"Persistent alteration of the skin microbiome in patients with skin rash after receiving EGFR inhibitor treatment","volume":"32","author":"Ashida","year":"2023","journal-title":"Exp. Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ctrv.2011.09.004","article-title":"Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review","volume":"38","author":"Baas","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"eabe2749","DOI":"10.1126\/sciimmunol.abe2749","article-title":"Persistence of mature dendritic cells, T H 2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R-alpha blockade","volume":"6","author":"Bangert","year":"2021","journal-title":"Sci. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e39706","DOI":"10.1371\/journal.pone.0039706","article-title":"Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor","volume":"7","author":"Bangsgaard","year":"2012","journal-title":"PLoS ONE"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.lungcan.2022.09.012","article-title":"Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach","volume":"173","author":"Basse","year":"2022","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/10781552251358871","article-title":"Comprehensive management strategies for amivantamab-induced toxicities and review of the literature","volume":"32","author":"Ceylan","year":"2026","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/imm.13152","article-title":"Skin barrier immunity and ageing","volume":"160","author":"Chambers","year":"2020","journal-title":"Immunology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102167","DOI":"10.1016\/j.ctim.2019.08.001","article-title":"Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: an updated meta-analysis of 23 randomized controlled trials","volume":"47","author":"Chen","year":"2019","journal-title":"Complementary Ther. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e72443","DOI":"10.7554\/elife.72443","article-title":"Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy","volume":"11","author":"Chen","year":"","journal-title":"eLife"},{"key":"B14","doi-asserted-by":"publisher","first-page":"156524","DOI":"10.1016\/j.phymed.2025.156524","article-title":"A topical Chinese herbal inhibits pruritus and skin inflammation via neural TRPM8 in atopic dermatitis","volume":"139","author":"Chen","year":"","journal-title":"Phytomedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaip.2024.10.027","article-title":"Class I HLA alleles Are associated with an increased risk of osimertinib-induced hypersensitivity","volume":"13","author":"Chen","year":"","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/ptr.70020","article-title":"Formononetin from Sophora flavescens aiton alleviates atopic dermatitis by suppressing neutrophil extracellular traps","volume":"39","author":"Cheng","year":"2025","journal-title":"Phytotherapy Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12016-024-09004-3","article-title":"Neutrophils in atopic dermatitis","volume":"67","author":"Chiang","year":"2024","journal-title":"Clin. Rev. Allergy & Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"15347354221118332","DOI":"10.1177\/15347354221118332","article-title":"Selective immune modulating activities of Viscum album and its components; A possibility of therapeutics on skin rash induced by EGFR inhibitors","volume":"21","author":"Choi","year":"2022","journal-title":"Integr. Cancer Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.molmed.2020.04.004","article-title":"Metabolic pathways that control skin homeostasis and inflammation","volume":"26","author":"Cibrian","year":"2020","journal-title":"Trends Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e70432","DOI":"10.1111\/cts.70432","article-title":"Cutaneous adverse effects of EGFR therapy in breast cancer treatment","volume":"18","author":"Devireddy","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jncc.2024.06.004","article-title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review","volume":"4","author":"Dong","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"B22","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666x.2021.1940962","article-title":"The IL-4, IL-13 and IL-31 pathways in atopic dermatitis","volume":"17","author":"Dubin","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"D1197","DOI":"10.1093\/nar\/gkaa1063","article-title":"HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine","volume":"49","author":"Fang","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"114896","DOI":"10.1016\/j.intimp.2025.114896","article-title":"Immunoregulatory effects of traditional Chinese medicine and its ingredients on psoriasis","volume":"159","author":"Feng","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"oyaf194","DOI":"10.1093\/oncolo\/oyaf194","article-title":"Mitigation and management of adverse events associated with amivantamab therapy","volume":"30","author":"Florez","year":"2025","journal-title":"Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1084\/jem.20112258","article-title":"Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation","volume":"209","author":"Franzke","year":"2012","journal-title":"J. Experimental Medicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jdv.18835","article-title":"Zinc supplements may prevent and treat cutaneous toxicities induced by epidermal growth factor receptor inhibitors","volume":"37","author":"Goncalo","year":"2023","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/ajco.13740","article-title":"Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta-analysis","volume":"18","author":"Gorji","year":"2022","journal-title":"Asia-Pacific J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"115428","DOI":"10.1016\/j.jep.2022.115428","article-title":"Jiu-Wei-Yong-An Formula suppresses JAK1\/STAT3 and MAPK signaling alleviates atopic dermatitis-like skin lesions","volume":"295","author":"Gu","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e79579","DOI":"10.2196\/79579","article-title":"Jiedu Xiaozhen granules for epidermal growth factor receptor tyrosine kinase inhibitor\u2013ediated skin toxicity: protocol for a randomized controlled trial","volume":"15","author":"Hao","year":"2026","journal-title":"JMIR Res. Protoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"35193","DOI":"10.18632\/oncotarget.17060","article-title":"Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash","volume":"8","author":"Hichert","year":"2017","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"154200","DOI":"10.1016\/j.phymed.2022.154200","article-title":"Therapeutic effects of myricetin on atopic dermatitis in vivo and in vitro","volume":"102","author":"Hou","year":"2022","journal-title":"Phytomedicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"154384","DOI":"10.1016\/j.phymed.2022.154384","article-title":"Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - smilax glabra Roxb herb pair for the treatment of psoriasis","volume":"105","author":"Hu","year":"2022","journal-title":"Phytomedicine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"118439","DOI":"10.1016\/j.jep.2024.118439","article-title":"Topical application of Artemisia annua L. essential oil ameliorates 2,4-dintrochlorobenzene-induced atopic dermatitis in mice","volume":"333","author":"Huang","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"115243","DOI":"10.1016\/j.intimp.2025.115243","article-title":"Oxymatrine for treating atopic dermatitis: network pharmacology, bioinformatics, metabolomics, and experimental validation","volume":"163","author":"Huang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.explore.2018.11.001","article-title":"Clinical experience of Chinese herbal medicine ameliorates dermatologic events from epidermal growth factor receptor inhibitors for lung cancer: a case series","volume":"15","author":"Hung","year":"2019","journal-title":"Explore (New York, N.Y.)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11912-026-01797-0","article-title":"Preventive and therapeutic interventions for anticancer drug-induced dermatologic toxicities: a scoping review","volume":"28","author":"Iimura","year":"2026","journal-title":"Curr. Oncol. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s10147-026-03044-9","article-title":"Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: a literature review by the Japanese Pharmacist-led Oncodermatology study team","volume":"31","author":"Iimura","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"115105","DOI":"10.1016\/j.bcp.2022.115105","article-title":"Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib","volume":"201","author":"Jiang","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1324930","DOI":"10.3389\/fimmu.2023.1324930","article-title":"A review of skin immune processes in acne","volume":"14","author":"Jin","year":"2023","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.7150\/ijms.122194","article-title":"Real-world safety of Anti-EGFR antibodies: 20-year pharmacovigilance of cetuximab and panitumumab","volume":"22","author":"Jin","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2020.01.001","article-title":"Management of EGFR inhibitor-induced skin toxicity and factors impacting patients' adherence to skin toxicity treatment: health care provider and patient surveys in European oncology centers","volume":"19","author":"Kafatos","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00520-025-09571-x","article-title":"Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy","volume":"33","author":"Kale","year":"2025","journal-title":"Support. Care Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00520-026-10896-4","article-title":"Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study","volume":"34","author":"Khongyot","year":"2026","journal-title":"Support. Care Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3390\/cancers12113120","article-title":"rhEGF treatment improves EGFR inhibitor-induced skin barrier and immune defects","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","first-page":"154318","DOI":"10.1016\/j.phymed.2022.154318","article-title":"Terminalia chebula Retz. extract ameliorates the symptoms of atopic dermatitis by regulating anti-inflammatory factors in vivo and suppressing STAT1\/3 and NF-kappaB signaling in vitro","volume":"104","author":"Kim","year":"2022","journal-title":"Phytomedicine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/0118744710249198231002055810","article-title":"A novel dual-labeled peptide for multimodal imaging of EGFR with L858R mutation","volume":"17","author":"Kim","year":"2024","journal-title":"Curr. Radiopharm."},{"key":"B48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/jco.2008.21.7828","article-title":"Skin toxicity evaluation protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support. Care Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2159-8290.cd-20-1847","article-title":"Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy","volume":"11","author":"Lacouture","year":"2021","journal-title":"Cancer Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"15347354221086663","DOI":"10.1177\/15347354221086663","article-title":"Efficacy of prophylactic traditional Chinese medicine on skin toxicity of afatinib in EGFR mutation-positive advanced lung adenocarcinoma: a single-center, prospective, double-blinded, randomized-controlled pilot trial","volume":"21","author":"Li","year":"","journal-title":"Integr. Cancer Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"804212","DOI":"10.3389\/fonc.2022.804212","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li","year":"","journal-title":"Front. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s1875-5364(23)60429-7","article-title":"Network pharmacology approaches for research of traditional Chinese medicines","volume":"21","author":"Li","year":"2023","journal-title":"Chin. J. Nat. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1645095","DOI":"10.3389\/fimmu.2025.1645095","article-title":"Mast cell\u2013euron axis as a core mechanism in chronic pruritus of atopic dermatitis: from mechanistic insights to therapeutic targets","volume":"16","author":"Li","year":"","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s10020-025-01279-2","article-title":"PIEZO1 promotes psoriasis-like skin inflammation in mice via NF-kappaB\/IL-17 signaling pathway activation","volume":"31","author":"Li","year":"","journal-title":"Mol. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cac2.70068","article-title":"CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer","volume":"45","author":"Liang","year":"2025","journal-title":"Cancer Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"199ra111","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"15347354251335598","DOI":"10.1177\/15347354251335598","article-title":"External application of a Xiaozhen zhiyang decoction for facial rash related to epidermal growth factor receptor tyrosine kinase inhibitors in Chinese patients: a prospective single-arm observational study","volume":"24","author":"Lin","year":"2025","journal-title":"Integr. Cancer Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE"},{"key":"B61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.intimp.2019.01.023","article-title":"Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor","volume":"69","author":"Liu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"835166","DOI":"10.3389\/fphar.2022.835166","article-title":"Reducing acneiform rash induced by EGFR inhibitors with honeysuckle therapy: a prospective, randomized, controlled study","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.cell.2023.03.031","article-title":"A tissue injury sensing and repair pathway distinct from host pathogen defense","volume":"186","author":"Liu","year":"2023","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e18761429386400","DOI":"10.2174\/0118761429386400250415053351","article-title":"Regulatory mechanisms of STAT3 in GBM and its impact on TMZ resistance","volume":"17","author":"Lv","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaci.2022.04.027","article-title":"Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis","volume":"150","author":"McCluskey","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1759-7714.15249","article-title":"Mechanism of action of adapalene for treating EGFR-TKI-induced skin disorder","volume":"15","author":"Mimura","year":"2024","journal-title":"Thorac. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"184","DOI":"10.31083\/j.fbl2905184","article-title":"From tumor to bone: growth factor receptors as key players in cancer metastasis","author":"Mohammad","year":"2024","journal-title":"Front. Biosci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3164\/jcbn.20-112","article-title":"Oxidative stress induces EGFR inhibition-related skin cell death","volume":"68","author":"Morita","year":"2021","journal-title":"J. Clin. Biochem. Nutr."},{"key":"B69","doi-asserted-by":"publisher","first-page":"108681","DOI":"10.1016\/j.pharmthera.2024.108681","article-title":"Bioactive lipids in the skin barrier mediate its functionality in health and disease","volume":"260","author":"Nicolaou","year":"2024","journal-title":"Pharmacol. & Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"118092","DOI":"10.1016\/j.jep.2024.118092","article-title":"Yu-Ping-Feng-San alleviates inflammation in atopic dermatitis mice by TLR4\/MyD88\/NF-kappaB pathway","volume":"329","author":"Nie","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/cad.0000000000001494","article-title":"EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines","volume":"34","author":"Nowaczyk","year":"2023","journal-title":"Anti-Cancer Drugs"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.061","article-title":"Cutaneous toxicities of small molecules in targeted cancer therapy part I \u2013Mechanisms of toxicity","author":"Nykaza","year":"2026","journal-title":"J. Am. Acad. Dermatology S0190-9622(26)00113-1"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1380453","DOI":"10.3389\/fonc.2024.1380453","article-title":"Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis","volume":"14","author":"O'Reilly","year":"2024","journal-title":"Front. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jncc.2024.12.005","article-title":"Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenes","volume":"5","author":"Pang","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/jco.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion\u2013utated non\u2013mall-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/tpj.2011.51","article-title":"Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity","volume":"13","author":"Parmar","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","article-title":"The epidermal growth factor receptor system in skin repair and inflammation","volume":"128","author":"Pastore","year":"2008","journal-title":"J. Investigative Dermatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00204-014-1244-4","article-title":"Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors","volume":"88","author":"Pastore","year":"2014","journal-title":"Archives Toxicol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e240223214012","DOI":"10.2174\/1874467216666230224104950","article-title":"Peptides for dual targeting of ErbB1 and ErbB2: blocking EGFR cell signaling transduction pathways for cancer chemotherapy","volume":"17","author":"Patnaik","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5582\/bst.2018.01246","article-title":"Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors","volume":"12","author":"Peng","year":"2018","journal-title":"Biosci. Trends"},{"key":"B81","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","article-title":"The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials","volume":"8","author":"Petrelli","year":"2013","journal-title":"Target. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/bjd.14756","article-title":"Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis","volume":"175","author":"Petrelli","year":"2016","journal-title":"Br. J. Dermatology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41590-022-01395-9","article-title":"Tissue adaptation and clonal segregation of human memory T cells in barrier sites","volume":"24","author":"Poon","year":"2023","journal-title":"Nat. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"100199","DOI":"10.1016\/j.lddd.2025.100199","article-title":"N'-([1,1'-Biphenyl]-4-ylmethylene)-4-methylbenzenesulfonohydrazide as a potential EGFR inhibitor: ADMET, docking, dynamics, and DFT studies","volume":"22","author":"Rajaraman","year":"2025","journal-title":"Lett. Drug Des. & Discov."},{"key":"B86","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.1007\/s00520-022-07254-5","article-title":"A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy","volume":"30","author":"Ramirez-Daffos","year":"2022","journal-title":"Support. Care Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jcp.21585","article-title":"Skin toxicity caused by EGFR antagonists\u2013n autoinflammatory condition triggered by deregulated IL-1 signaling?","volume":"218","author":"Rodeck","year":"2009","journal-title":"J. Cell. Physiology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.curpro.2025.100004","article-title":"Design, synthesis, and theoretical studies of sulfonylated purine derivatives as EGFR inhibitor","volume":"22","author":"Saha","year":"2025","journal-title":"Curr. Proteomics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.3390\/cancers14215308","article-title":"The riddle of cetuximab-related skin toxicity","volume":"14","author":"Saorin","year":"2022","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/jci128678","article-title":"IL-36gamma drives skin toxicity induced by EGFR\/MEK inhibition and commensal Cutibacterium acnes","volume":"130","author":"Satoh","year":"2020","journal-title":"J. Clin. Investigation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1408474","DOI":"10.3389\/fimmu.2024.1408474","article-title":"Traditional Chinese herbal medicine: harnessing dendritic cells for anti-tumor benefits","volume":"15","author":"Shen","year":"2024","journal-title":"Front. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12032-025-03193-3","article-title":"Drug-induced cutaneous toxicities in solid tumor oncology: mechanisms, manifestations, and management","volume":"43","author":"Skossyrskiy","year":"2025","journal-title":"Med. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s44321-024-00166-3","article-title":"JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia","volume":"16","author":"Strobl","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1158\/0008-5472.can-09-0487","article-title":"Tumor necrosis factor-alpha and Interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice","volume":"69","author":"Surguladze","year":"2009","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"618897","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2021","journal-title":"Front. Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11864-025-01333-5","article-title":"Skin reactions and other underappreciated dermatologic side effects of cancer therapies","volume":"26","author":"Tran","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e20510","DOI":"10.1097\/md.0000000000020510","article-title":"Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer","volume":"99","author":"Tseng","year":"2020","journal-title":"Medicine"},{"key":"B98","doi-asserted-by":"publisher","first-page":"108950","DOI":"10.1016\/j.lungcan.2026.108950","article-title":"Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm","volume":"213","author":"Vasiliki","year":"2026","journal-title":"Lung Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s10753-020-01281-2","article-title":"Gefitinib-Induced cutaneous toxicities in brown Norway rats are associated with macrophage infiltration","volume":"43","author":"Wan","year":"2020","journal-title":"Inflammation"},{"key":"B100","doi-asserted-by":"publisher","first-page":"154346","DOI":"10.1016\/j.phymed.2022.154346","article-title":"Anti-atopic dermatitis effect of a modified huang-lian-jie-du decoction and its active fraction on 2,4-dinitrobenzene and MC903-induced mouse models","volume":"104","author":"Wang","year":"2022","journal-title":"Phytomedicine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"116923","DOI":"10.1016\/j.jep.2023.116923","article-title":"Qingre Qushi formula suppresses atopic dermatitis via a multi-target mechanism","volume":"318","author":"Wang","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"107890","DOI":"10.1016\/j.phrs.2025.107890","article-title":"Extracellular vesicles: a new frontier in deciphering the mechanisms of traditional Chinese medicine","volume":"219","author":"Wang","year":"","journal-title":"Pharmacol. Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1629288","DOI":"10.3389\/fimmu.2025.1629288","article-title":"Research progress on traditional Chinese medicine compounds in autoimmune-related skin diseases","volume":"16","author":"Wang","year":"","journal-title":"Front. Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/ptr.70310","article-title":"Glycyrrhizic acid alleviates Osimertinib-induced cutaneous toxicity by inhibiting Keratinocyte apoptosis and inflammation","volume":"40","author":"Wang","year":"2026","journal-title":"Phytotherapy Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"107276","DOI":"10.1016\/j.fitote.2026.107276","article-title":"Xiao Zhen Fang mitigates cutaneous toxicity by inhibiting PANoptosis: insights from untargeted metabolomics and transcriptomics","volume":"192","author":"Wang","year":"2026","journal-title":"Fitoterapia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1083432","DOI":"10.3389\/fmicb.2022.1083432","article-title":"The role of short-chain fatty acids in inflammatory skin diseases","volume":"13","author":"Xiao","year":"2023","journal-title":"Front. Microbiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1016\/j.jid.2022.04.026","article-title":"Prophylactic effect of nitric oxide donors on rat models of EGFR inhibitor-induced cutaneous toxicities","volume":"142","author":"Xie","year":"2022","journal-title":"J. Investigative Dermatology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"154925","DOI":"10.1016\/j.phymed.2023.154925","article-title":"Jingfang granules exert anti-psoriasis effect by targeting MAPK-mediated dendritic cell maturation and PPAR-gamma-mediated keratinocytes cell cycle progression in vitro and in vivo","volume":"117","author":"Xu","year":"2023","journal-title":"Phytomedicine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.3390\/ijms21082867","article-title":"Skin barrier abnormalities and immune dysfunction in atopic dermatitis","volume":"21","author":"Yang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/s1875-5364(24)60746-6","article-title":"Traditional Chinese medicine-based drug delivery systems for anti-tumor therapies","volume":"22","author":"Yang","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"eabq7074","DOI":"10.1126\/scitranslmed.abq7074","article-title":"Topical JAK inhibition ameliorates EGFR inhibitor\u2013nduced rash in rodents and humans","volume":"16","author":"You","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1097\/js9.0000000000004704","article-title":"From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy","volume":"112","author":"Yu","year":"2026","journal-title":"Int. J. Surg."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan","year":"2023","journal-title":"J. Cosmet. Dermatology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41590-025-02145-3","article-title":"Cutaneous T cell immunity","volume":"26","author":"Zareie","year":"2025","journal-title":"Nat. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"440","DOI":"10.7555\/jbr.36.20220065","article-title":"Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Biomed. Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/jir.s441100","article-title":"Microbiome: role in inflammatory skin diseases","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e70145","DOI":"10.1111\/exd.70145","article-title":"Mechanism study on inhibition of EPHA2 expression impaired skin barrier function by gefitinib","volume":"34","author":"Zhang","year":"2025","journal-title":"Exp. Dermatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1002034","DOI":"10.3389\/fimmu.2022.1002034","article-title":"Global research trends on precision cancer medicine-related rashes (2008-2021): a bibliographic study","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.jep.2023.116306","article-title":"Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula","volume":"309","author":"Zhao","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"156543","DOI":"10.1016\/j.phymed.2025.156543","article-title":"Jinkui Shenqi decoction targets PAD4 to restrain NETosis and ameliorates psoriasis progression","volume":"139","author":"Zhao","year":"2025","journal-title":"Phytomedicine"},{"key":"B121","doi-asserted-by":"publisher","first-page":"113437","DOI":"10.1016\/j.yexcr.2022.113437","article-title":"Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis","volume":"423","author":"Zheng","year":"2023","journal-title":"Exp. Cell Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"111913","DOI":"10.1016\/j.cellsig.2025.111913","article-title":"Acetaldehyde dehydrogenase 1A1 upregulation drives dacomitinib-induced skin toxicity through mitochondrial dysfunction and keratinocyte apoptosis","volume":"134","author":"Zhou","year":"2025","journal-title":"Cell. Signal."},{"key":"B123","doi-asserted-by":"publisher","first-page":"154018","DOI":"10.1016\/j.tox.2024.154018","article-title":"EGFR-TKIs induce acneiform rash and xerosis via Caspase-3\/GSDME-mediated pyroptosis of keratinocytes and sebocytes","volume":"511","author":"Zhu","year":"2025","journal-title":"Toxicology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1029818","DOI":"10.3389\/fimmu.2022.1029818","article-title":"Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations","volume":"13","author":"Zouboulis","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1931462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:35:54Z","timestamp":1790069754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1931462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":124,"alternative-id":["10.3389\/fphar.2026.1931462"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1931462","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1931462"}}